Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
暂无分享,去创建一个
R. Munden | J. Bruzzi | H. Kantarjian | J. Cortes | A. Quintás-Cardama | S. O'brien | G. Borthakur | A. Quintás-Cardama
[1] R. Larson,et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. , 2007, Blood.
[2] M. Baccarani,et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. , 2007, Blood.
[3] M. Baccarani,et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. , 2007, Blood.
[4] H. Kantarjian,et al. Dasatinib (SPRYCEL®) 140 mg Once Daily (QD) vs 70 mg Twice Daily (BID) in Patients (pts) with Advanced Phase Chonic Myeloid Leukemia (ABP-CML) or Ph(+) ALL Who Are Resistant or Intolerant to Imatinib (im): Results of the CA180-035 Study. , 2006 .
[5] H. Kantarjian,et al. Dasatinib (SPRYCEL®) 50mg or 70mg BID Versus 100mg or 140mg QD in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Resistant or Intolerant to Imatinib: Results of the CA180-034 Study. , 2006 .
[6] T. Brümmendorf,et al. A Phase 1/2 Study of SKI-606, a Dual Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) Relapsed, Refractory or Intolerant of Imatinib. , 2006 .
[7] Yeon-Hee Park,et al. BNP as a marker of the heart failure in the treatment of imatinib mesylate. , 2006, Cancer letters.
[8] L. Scapozza,et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. , 2006, Cancer research.
[9] Susan O'Brien,et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.
[10] F. Lee,et al. BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo , 2005 .
[11] B. Druker,et al. Oncogenes and Tumor Suppressors (795 articles) , 2004 .
[12] G J M Parker,et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Latagliata,et al. Pleural‐pericardic effusion as uncommon complication in CML patients treated with Imatinib , 2005, European journal of haematology.
[14] Ping Chen,et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.
[15] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[16] Neil O. Carragher,et al. A Novel Role for FAK as a Protease-Targeting Adaptor Protein Regulation by p42 ERK and Src , 2003, Current Biology.
[17] D. Hanahan,et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.
[18] N. Carragher,et al. Calpain: a role in cell transformation and migration. , 2002, The international journal of biochemistry & cell biology.
[19] R. Goldsby,et al. Unexpected pleural effusions in 3 pediatric patients treated with STI-571. , 2002, Journal of pediatric hematology/oncology.
[20] Sante Tura,et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.
[21] J. Kuriyan,et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.
[22] Alan S Maisel,et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.
[23] R. Larson,et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.
[24] M. Baccarani,et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.
[25] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[26] S. Courtneidge,et al. Src family tyrosine kinases and growth factor signaling. , 2000, Experimental cell research.
[27] M. Sudol,et al. The SRC family protein tyrosine kinase p62yes controls polymeric IgA transcytosis in vivo. , 1999, Molecular cell.
[28] C. Betsholtz,et al. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. , 1999, Development.
[29] S. Sahn,et al. Drugs and the pleura. , 1999, Chest.
[30] B R Johansson,et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. , 1997, Science.
[31] Sheila M. Thomas,et al. Cellular functions regulated by Src family kinases. , 1997, Annual review of cell and developmental biology.
[32] W. C. Ball,et al. Pleural effusions: the diagnostic separation of transudates and exudates. , 1972, Annals of internal medicine.